Role of pantoprazole in the treatment of gastro-oesophageal reflux disease
- PMID: 15709887
- DOI: 10.1517/14656566.6.1.93
Role of pantoprazole in the treatment of gastro-oesophageal reflux disease
Abstract
The diagnosis and treatment of gastro-oesophageal reflux disease (GERD) presents many problems, despite the fact that significant advances have been made in recent years in the understanding of its pathogenesis and symptomatology. GERD affects many people and has a significant negative impact on patient quality of life. Heartburn is the most common symptom of GERD which occurs with and without oesophagitis. The predominant causative factor for symptoms is prolonged contact of oesophageal mucosa with refluxed acid and pepsin. Proton pump inhibitors (PPIs) are the most effective treatment for GERD: overall proportions of patients with healing and complete heartburn relief are markedly higher with PPIs than with alternative treatment strategies. Furthermore, the speed of healing and heartburn relief with PPIs is almost twice as rapid as with any other form of therapy. The present review focuses on the effectiveness and safety of the PPI, pantoprazole. The data show that the compound is highly effective in GERD patients with and without oesophagitis. Pantoprazole has an excellent safety record and shows only minor interaction with other drugs.
Similar articles
-
Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.Am J Gastroenterol. 2001 Oct;96(10):2849-57. doi: 10.1111/j.1572-0241.2001.4237_a.x. Am J Gastroenterol. 2001. PMID: 11695354 Clinical Trial.
-
Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.Clin Ther. 2001 Jul;23(7):998-1017. doi: 10.1016/s0149-2918(01)80087-4. Clin Ther. 2001. PMID: 11519776
-
A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis.Aliment Pharmacol Ther. 1998 Jan;12(1):49-52. doi: 10.1046/j.1365-2036.1998.00278.x. Aliment Pharmacol Ther. 1998. PMID: 9692700 Clinical Trial.
-
The pharmacology and clinical relevance of proton pump inhibitors.Curr Gastroenterol Rep. 2002 Dec;4(6):459-62. doi: 10.1007/s11894-002-0021-3. Curr Gastroenterol Rep. 2002. PMID: 12441035 Review.
-
Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.J Am Pharm Assoc (Wash). 2000 Jan-Feb;40(1):52-62; quiz 121-3. doi: 10.1016/s1086-5802(16)31036-1. J Am Pharm Assoc (Wash). 2000. PMID: 10665250 Review.
Cited by
-
Pilot study of on-demand therapy with pantoprazole 20mg for long-term treatment in patients with mild gastro-oesophageal reflux disease.Clin Drug Investig. 2005;25(10):633-42. doi: 10.2165/00044011-200525100-00002. Clin Drug Investig. 2005. PMID: 17532708
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical